

## PROGRAMME OF LIVE SESSIONS: **CEST timing**

The programme below will take place live. This time schedule corresponds to **CEST timing**. [Click here](#) to adapt the CEST time schedule to your own time zone.

If you want to ask questions during the Panel Discussions and Round Tables or if you want to test your knowledge and vote during Interactive Case presentations and debates, please make sure that you join us at the times indicated below.

Please also note that the Meet the Expert sessions and the Mentored Poster Walk will take place 100% live. To interact you must be online at the times indicated in the programme below.

Thank you for joining us. We wish you a good meeting



### **3<sup>rd</sup> How to Diagnose and Treat Multiple Myeloma April 15-18, 2021**

**Chairs : Hermann Einsele, Irene Ghobrial, Sonja Zweegman**

#### **Thursday, April 15, 2021**

**14:00-14:05 Welcome : Hermann Einsele, Irene Ghobrial, Sonja Zweegman**

#### **SESSION I – How I treat smoldering myeloma (SMM)**

**Chair:** Irene Ghobrial (Boston)

14:05-14:10	Introduction	Irene Ghobrial (Boston)
14:10-14:30	Interactive case: Smoldering myeloma	Maria-Victoria Mateos (Salamanca)
14:30-14:50	Case-based lecture: High risk smoldering myeloma	Irene Ghobrial (Boston)
14:50-15:10	Case-based lecture: Understanding the immune ME of SMM	Madhav Dhodapkar (Atlanta)
15:10-15:30	Case-based lecture: Imaging with PET-CT in SMM	Cristina Nanni (Bologna)
15:30-15:35	<u>Brief oral communication</u> <i>Early diagnosis of multiple myeloma by means of a computer-aided algorithm</i>	<i>Maria Salinas (Alicante)</i>

*15:35-16:05 Panel discussion*

**16:05-16:15 Coffee break**

#### **SESSION II – How I treat newly diagnosed multiple myeloma**

**Chair:** Sonja Zweegman (Amsterdam)

16:15-16:20	Introduction	Sonja Zweegman (Amsterdam)
16:20-16:40	Interactive case: Newly diagnosed transplant eligible multiple myeloma	Karthik Ramasamy (Oxford)
16:40-17:00	Case-based lecture : Tandem transplant in the Dara-era?	Charlotte Pawlyn (London)
17:00-17:20	Case-based lecture: Are all frail patients frail?	Sonja Zweegman (Amsterdam)
17:20-17:40	Case-based lecture : Novel therapeutic approaches for frail multiple myeloma patients	Alessandra Larocca (Turin)
17:40-17:45	<u>Brief oral communication</u> <i>Daratumumab plus Lenalidomide, Bortezomib, and Dexamethasone in patients with transplant-eligible newly diagnosed multiple myeloma: updated analysis of GRIFFIN after 12 months of maintenance therapy</i>	Peter M. Voorhees (Charlotte)
17:45-18:15	Panel discussion	
18:25-19:25	<b>Mentored Poster Walk</b>	Martin Kortüm (Würzburg), Charlotte Pawlyn (London)

## Friday, April 16, 2021

### 13:30-14:30 SATELLITE SYMPOSIUM

**Targeting the immune system in multiple myeloma: CAR T cell therapy and beyond**

**Chair:** Xavier Leleu (Poitiers)

**Speakers:** Xavier Leleu (Poitiers), Niels van de Donk (Amsterdam), Nikhil Munshi (Boston)

*This symposium is organized and sponsored by Bristol Myers Squibb*

### SESSION III – From risk stratification to risk-based therapy?

**Chair:** Hermann Einsele (Würzburg)

14:40-14:45	Introduction	Hermann Einsele (Würzburg)
14:45-15:05	Interactive case: How I treat a high risk patient	Faith Davies (New York)
15:05-15:25	Case-based lecture : NGS guided targeted and immune therapies in multiple myeloma	Samir Parekh (New York)
15:25-15:45	Case-based lecture : Genome-based targeted immunotherapy	Leo Rasche (Würzburg)
15:45-16:05	Case-based lecture : My DRUG - precision intervention in multiple myeloma	Daniel Auclair (Boston)
16:05-16:40	Panel discussion	
16:40-16:50	<b>Coffee break</b>	
16:50-17:45	<b>DEBATE 1 – Should we use MRD testing to determine therapy in multiple myeloma?</b> <b>Chair:</b> Ola Landgren (Miami)	

16:50-16:55 Introduction Ola Landgren (Miami)  
*Audience votes YES or NO*  
16:55-17:10 YES Nikhil Munshi (Boston)  
17:10-17:25 NO Angela Dispenzieri (Rochester)  
17:25-17:45 *Discussion*

*Audience votes again YES or NO*

**17:45-18:40 DEBATE 2 – Is there a future role of autologous stem cell transplantation?**  
**Chair:** Francesca Gay (Turin)

17:45-17:50 Introduction Francesca Gay (Turin)  
*Audience votes YES or NO*  
17:50-18:05 YES Salomon Manier (Lille)  
18:05-18:20 NO Ola Landgren (Miami)  
18:20-18:40 *Discussion*

*Audience votes again YES or NO*

**18:50-19:50 3 Simultaneous Meet the Expert sessions**

1. How to sequence therapy in RRMM Xavier Leleu (Poitiers) and Inger Nijhof (Amsterdam)
2. How to prevent and treat side effects of immune therapy Niels van de Donk (Amsterdam) and Nina Shah (San Francisco)
3. How to deal with small plasma cell clones leading to clinical symptoms Angela Dispenzieri (Rochester) and Joan Blade (Barcelona)

**Saturday, April 17, 2021**

**09:00-10:00 SATELLITE SYMPOSIUM**

**Management of Relapsed and Refractory Multiple Myeloma with novel monoclonal antibody-based regimens - From evidence-based considerations to clinical practice**

**Chair:** Hartmut Goldschmidt (Heidelberg)

**Speakers:** Philippe Moreau (Nantes), Kwee Yong (London), Sonja Zweegman (Amsterdam)

***This symposium is organised and funded by Sanofi***

**10:00-10:10 Coffee break**

**SESSION IV – How I treat relapsed multiple myeloma**

**Chair :** Philippe Moreau (Nantes)

10:10-10:15 Introduction Philippe Moreau (Nantes)

10:15-10:35	Interactive case: Relapsed multiple myeloma	Xavier Leleu (Poitiers)
10:35-10:55	Case-based lecture : How I treat first relapse	Paula Rodriguez-Otero (Pamplona)
10:55-11:15	Case-based lecture : How I treat later relapses	Stefan Knop (Würzburg)
11:15-11:35	Case-based lecture : Novel agents in relapsed multiple myeloma	Enrique Ocio (Santander)
11:35-11:45	<u>Brief oral communications</u>	
11:35-11:40	<i>Talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) X CD3 bispecific antibody, in patients with relapsed and/or refractory multiple myeloma (RRMM): results from an ongoing phase 1 study</i>	Albert Oriol (Barcelona)
11:40-11:45	<i>HORIZON (OP-106): Melflufen plus Dexamethasone in 55 patients with relapsed/refractory multiple myeloma (RRMM) with extramedullary disease (EMD)—subgroup analysis</i>	Paul G. Richardson (Boston)
11:45-12:10	<i>Panel discussion</i>	
<b>12:10-13:05</b>	<b>DEBATE 3 – Should every patient receive daratumumab in first line?</b>	
	<b>Chair:</b> Niels van de Donk (Amsterdam)	
12:10-12:15	Introduction	Niels van de Donk (Amsterdam)
	<i>Audience votes YES or NO</i>	
12:15-12:30	YES	Philippe Moreau (Nantes)
12:30-12:45	NO	Fredrik Schjesvold (Oslo)
12:45-13:05	<i>Discussion</i>	
	<i>Audience votes again YES or NO</i>	
<b>13:05-14:45</b>	<b>Lunch</b>	

**13:35-14:35 SATELLITE SYMPOSIUM**  
**New era, new data, new implications for managing multiple myeloma**  
**Speakers:** Mohamad Mohty (Paris), Philippe Moreau (Nantes)

*This symposium is supported by Janssen Pharmaceutical Companies of Johnson & Johnson in EMEA*

<b>14:45-15:55</b>	<b>ROUNDTABLE – Novel agents in the treatment of multiple myeloma from the perspective of FDA/EMA and Foundations</b>	
	<b>Chairs:</b> Hermann Einsele (Würzburg) and Sonja Zweegman (Amsterdam)	
14:45-14:50	Introduction	Hermann Einsele (Würzburg), Sonja Zweegman (Amsterdam)
14:50-15:05	Food and Drug Administration	Bindu Kanapuru (Bethesda)

15:05-15:20	Multiple Myeloma Research Foundation perspective: Multiple myeloma drug development in 2021	Daniel Auclair (Boston)
15:20-15:35	Access to drugs in Europe	Jean-Luc Harousseau (Nantes)
15:35-15:55	<i>Discussion</i>	
<b>15:55-16:05 Coffee break</b>		
<b>SESSION V- You can't be immune for immune therapy anymore</b>		
<b>Chair:</b> Hermann Einsele (Würzburg)		
16:05-16:10	Introduction	Hermann Einsele (Würzburg)
16:10-16:30	Interactive case: Bi- and trispecific antibodies in multiple myeloma	Hermann Einsele (Würzburg)
16:30-16:50	Case-based lecture : CART in multiple myeloma	Nina Shah (San Francisco)
16:50-17:10	Case-based lecture : Antibody based immunotherapy	Niels Van De Donk (Amsterdam)
17:10-17:30	Case-based lecture : Future immunotherapies in multiple myeloma	Eric Smith (New York)
17:30-17:40	<u>Brief oral communications</u>	
17:30-17:35	<i>Cartitude-1, a phase 1b/2 study of Ciltacabtagene Autoleucl in relapsed/refractory multiple myeloma (RRMM)</i>	<i>Deepu Madduri (New York)</i>
17:35-17:40	<i>Teclistamab, a B-Cell maturation antigen (BCMA) X CD3 bispecific antibody, in relapsed and/or refractory multiple myeloma (RRMM): updated phase 1 results</i>	<i>Hareth Nahi (Stockholm)</i>
17:40-18:10	<i>Panel discussion</i>	

## Sunday, April 18, 2021

**10:20-11:20 SATELLITE SYMPOSIUM**  
**Anti B-cell maturation antigen (BCMA) :**  
**the fourth pillar treatment in relapsed/refractory multiple myeloma**  
**Chair:** Xavier Leleu (Poitiers)  
**Speakers:** Javier de la Rubia (Valencia), Elena Zamagni (Bologna)

*This symposium is organised and funded by GSK*

## SESSION VI – Other plasma cell dyscrasias

**Chair:** Elena Zamagni (Bologna)

11:30-11:35	Introduction	Elena Zamagni (Bologna)
11:35-11:55	Interactive case: How I treat Waldenstrom's macroglobulinemia	Josephine Vos (Amsterdam)
11:55-11:15	Case-based lecture: How I treat amyloidosis	Giampaolo Merlini (Pavia)

- 11:15-12:35 Case-based lecture: Stefan Knop (Würzburg)  
Is this myeloma kidney? A case of significantly elevated free serum light chains and kidney failure
- 12:35-12:55 Case-based lecture: How to treat bone disease Elena Zamagni (Bologna)  
in multiple myeloma
- 12:55-13:00 Brief oral communication  
*Reductions in absolute iFLC and dFLC are associated with Efstathios Kastritis (Athens)*  
*prolonged major organ deterioration progression-free survival in patients with newly diagnosed AL*  
*amyloidosis receiving VCD with or without Daratumumab: results from ANDROMEDA*
- 13:00- 13:30 *Panel discussion*
- 13:30-14:00 Lunch**
- 14:00-15:00 KEYNOTE LECTURES:**  
**The future of multiple myeloma**  
**Chair:** Kenneth C. Anderson (Boston)
- 14:00-14:05 Introduction Kenneth C. Anderson (Boston)
- 14:05 -14.25 There is no future without past Kenneth C. Anderson (Boston)
- 14.25 - 14:45 The future is now, science fiction thereafter Francesca Gay (Turin)
- 14:45-15:00 *Discussion*
- 15:00-15:05 Closing remarks**

**MEETING CLOSURE**